Acute hepatic porphyrias

被引:1
|
作者
Sayk, Friedhelm [1 ]
Grasshoff, Lars [1 ]
机构
[1] Univ Klinikum Schleswig Holstein, Allgemeine Innere Med, Med Klin I, Ratzeburger Allee 160,Campus Lubeck, D-23538 Lubeck, Germany
关键词
Inborn genetic diseases; Acute intermittent porphyria; Abdominal pain; delta-Aminolaevulinic acid; Porphyrins; UPDATE;
D O I
10.1007/s00063-022-00978-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute porphyrias are caused by rare hereditary disorders of hepatic heme biosynthesis. Episodes of accumulating neurotoxic metabolites lead to multisystemic symptoms such as visceral pain, autonomic dysregulation, neurocognitive impairment, hyponatremia, and occasionally motor paralysis. In addition to protracted non-emergency courses, acute life-threatening crises can occur, often triggered by infection, medication, fasting, or hormonal stimuli. Since the clinical presentation is nonspecific and multifaceted, many patients have gone through a long odyssey until they receive a diagnosis. Acute attacks often lead to presenting initially to the emergency department, where acute hepatic porphyria (AHP) is easily overlooked in the differential diagnosis. Establishing the diagnosis requires a high level of genuine suspicion (e.g., cluster of signs and symptoms along with certain patterns of health care resource utilization). The initial diagnostic work-up requires the measurement of metabolites in the urine. Emergency management consists of infusions of glucose and heme arginate along with symptomatic therapy. However, porphyrinogenic agents must be strictly avoided (). After initial diagnosis, a thorough work-up should be done at a porphyria center (confirming the diagnosis, education, genetic counselling) and issuance of an emergency identification card is mandatory. If the frequency of relapses is high, new targeted prophylactic therapies have proven effective. Patients with known porphyria require special attention in any acute medical condition in order to avoid porphyrinogenic triggers and to exclude threatening differential diagnosis (e.g., sepsis) by consistent basic diagnostics.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [21] Novel treatment options for acute hepatic porphyrias
    Wang, Bruce
    CURRENT OPINION IN GASTROENTEROLOGY, 2021, 37 (03) : 194 - 199
  • [22] Frequency of malignant tumors in the acute hepatic porphyrias
    Lang, E.
    Schaefer, M.
    Schwender, H.
    Neumann, N. J.
    Frank, J.
    EXPERIMENTAL DERMATOLOGY, 2015, 24 (03) : E16 - E16
  • [23] Givosiran, a novel treatment for acute hepatic porphyrias
    Thapar, Manish
    Rudnick, Sean
    Bonkovsky, Herbert L.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 9 - 18
  • [24] New Therapy Option for acute hepatic Porphyrias
    Petrides, Petro E.
    K. Beykirch, Maria
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (23) : 1576 - 1577
  • [25] Acute hepatic porphyrias: Current diagnosis & management
    Anderson, Karl E.
    MOLECULAR GENETICS AND METABOLISM, 2019, 128 (03) : 219 - 227
  • [26] ACUTE HEPATIC PORPHYRIAS - A STUDY ON 530 CASES
    DOSS, MO
    MOLECULAR ASPECTS OF MEDICINE, 1990, 11 (1-2) : 44 - 45
  • [27] Acute hepatic porphyrias for the neurologist: current concepts and perspectives
    Sgobbi de Souza, Paulo Victor
    Lombardi Badia, Bruno de Mattos
    Farias, Igor Braga
    Goncalves, Eduardo Augusto
    Vieira de Rezende Pinto, Wladimir Bocca
    Bulle Oliveira, Acary Souza
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (01) : 68 - 80
  • [28] HEPATIC PORPHYRIAS
    DOSS, M
    ACTA MEDICA AUSTRIACA, 1984, 11 (02) : 54 - &
  • [29] HEPATIC PORPHYRIAS
    不详
    BMJ-BRITISH MEDICAL JOURNAL, 1971, 2 (5756): : 235 - +
  • [30] Hepatic porphyrias
    Doss, MO
    MEDIZINISCHE KLINIK, 1997, 92 (12): : 745 - 746